(AOF) – Adocia announces a cash position of 16.8 million euros as of September 30, 2023 “following operations carried out in the third quarter of 2023”. The biotech specialist in diabetes has nine-month turnover of 1.9 million euros compared to 9.7 million a year ago. It commits to the pursuit of a policy of “cost reduction and project prioritization”. “Our cash position of nearly 17 million euros allows us to finance our activities until the end of July 2024,” indicates Valérie Danaguezian, Financial and Administrative Director.
Cash consumption linked to activities for the first nine months of the year amounted to 10.6 million euros, lower than last year (14 million euros), on a comparable basis (excluding operations financing).
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
